CNBX Pharmaceuticals Inc.: 3i, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
3i, LP amended its Schedule 13G filing on CNBX Pharmaceuticals Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-126207. The filing, submitted via SEC EDGAR, revises the fund's previously reported position in the pharmaceutical company. The amendment signals a change in 3i's holdings, though the filing itself does not specify the direction or size of the adjustment. Investors should watch for further 13G or 13D filings to confirm whether 3i is accumulating or reducing its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CNBX Pharmaceuticals Inc., 3i, LP